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Abstract 
For the purpose of engineering the antibody combining site, mapping residues that are involved in antigen binding provide us with valuable 
information. By use of t3C NMR spectroscopy with selectively ~3C-labeled Fv fragments, we have established a general strategy to identify the residues 
that are perturbed upon binding of small antigen (hapten) molecules [(1990) Biochemistry 30, 6604--6610]. In the present paper, we demonstrate that 
this strategy can be extended to molecular structural nalyses of the complexes of an Fab fragment and a larger antigen molecule such as Pseudomonas 
aeruginosa exotoxin A with a molecular mass of 67 kDa, 
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1. Introduction 
Since hybridoma technology was established, mono- 
clonal antibodies have been widely used as immuno- 
chemical tools, diagnostic reagents, and therapeutics. 
Recently, genetically engineered antibodies have been 
produced in order to improve specific reactivity with 
target antigens, to reduce antigenicity for human ther- 
apy, and to control the expression of effector functions 
[1]. The antigen combining site in the antibody molecule 
is particularly attractive as a target for antibody engi- 
neering including the design of catalytic antibodies. With 
the knowledge of the structure of the antigen combining 
site, one could make an improved antibody with a higher 
binding affinity by a conventional method such as site- 
directed mutagenesis. Hence, the mapping of residues 
involved in paratope would be crucial. 
X-ray crystallography is a powerful method in identi- 
fying the residues involved in the antigen binding on the 
basis of three-dimensional structural data (for a review, 
see Padlan, [2]). However, it is not always possible to 
prepare the crystal of antigen-antibody complexes with 
* Corresponding author. Fax: (81) (3) 3813 5099. 
Abbreviations: CDR, complementarity-determining region; Cnl, the 
first domain of the constant region of the heavy chain; CL, constant 
region of the light chain; DNS-Lys, Ne-dansyl-L-lysine; Ex-A, Pseudo- 
monas aeruginosa exotoxin A; Fab, antigen binding fragment composed 
ofVn, VL, CH1, and CL; [X]Fab, Fab labeled with [1-13C]X; [X,Z]Fab, 
Fab that is labeled with [1J3C]X and [ct-tSN]Z; Fv, antigen binding 
fragment composed of Vn and VL; IgG, immunoglobulin G; NMR, 
nuclear magnetic resonance; SDS-PAGE, sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis; Vn, variable region of the heavy chain; 
VL, variable region of the light chain. 
high quality. NMR spectroscopy is an alternative way to 
obtain structural information on ligand-protein terac- 
tions. However, the size of IgG (Mr ~ 150 K) or its Fab 
fragment (Mr ~ 50 K) hampers detailed structural nalyses 
by traditional NMR spectroscopy. To cope with this 
problem, Anglister and coworkers have developed strat- 
egies for 1H NMR spectral analyses using selective deu- 
teration of Fab fragments (for a review, see Anglister, 
[3]). We have developed a variety of heteronuclear NMR 
techniques for the investigation ofaffinity maturation by 
use of Fab fragments [4]. In these studies, however, the 
problem of site-specific resonance assignments remained 
to be solved. 
Recently, by use of Fv fragments (Mr ~25 K) labeled 
with ~3C and/or lSN, it has become possible to identify 
residues involved in the antigen binding using 1H-de- 
tected heteronuclear NMR spectroscopy [5-9]. However, 
almost all of the materials used so far as antigens in these 
NMR studies were limited to small molecules uch as 
haptens or peptides. In addition, the large amount of 
stable Fv fragments hat is needed for the NMR analysis 
has not always been available. Taking into account of all 
the above points, it is obviously necessary toestablish an 
NMR strategy on the basis of unambiguous spectral 
assignments o deal with the complexes of Fab with a 
larger antigen. 
For the spectral analyses of large antigen-Fab com- 
plexes with molecular mass more than 100 kDa, only 
possible way envisaged is the use of carbonyl ~3C reso- 
nances as spectroscopic probes. In the previous papers, 
we have demonstrated that 13C NMR methods on the 
basis of unambiguous assignmets of carbonyl 13C reso- 
nances by a 13C-15N double labeling technique [10] pro- 
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vide us with detailed structural information from large 
proteins [11-15]. We have also revealed that the chemical 
shift of the carbonyl 13C resonances sensitively reflects 
microenvironmental changes in Fv fragments induced by 
hapten binding and, therefore, can be a useful tool for 
the mapping of antigen binding sites [12, 13]. In the 
present study, we apply this strategy to much larger sys- 
tems, i.e. hapten-Fab and protein antigen-Fab com- 
plexes. Applicability of the strategy to molecular struc- 
tural analyses of a complex of Pseudomonas eruginosa 
exotoxin A (Ex-A) with a molecular mass of 67 kDa and 
an anti-Ex-A Fab fragment will be examined. 
2. Materials and methods 
2.1. Materials 
L-[1-13C]Met was purchased from Isotec, Inc., USA. L-[~-lSN]His was 
from Isocommerz GmbH, Germany. All other ~3C- or 15N-labeled 
amino acids were purchased from ICON Service Inc., USA. The isotope 
enrichment is 95% or higher for each of these amino acids, fl-Chloro- 
L-alanine, Ne-dansyl-L-Lys (DNS-Lys), and papain were purchased 
from Sigma. Ex-A produced by and purified from Pseudomonas erug- 
inosa was purchased from Swiss Serum and Vaccine Institute Berne, 
Switzerland. 
2.2. Cell lines 
Switch variant cell lines 27--44, 27-13.6, and 27-35.8, which had been 
selected and cloned by using a fluorescence-activated cell sortor [16, 17], 
were kindly provided by Professor L.A. Herzenberg and Dr. V.T. Oi. 
These cell lines produce mouse monoclonal anti-dansyl IgG1Qc), 
IgG2a(t¢), and IgG2b(t¢), respectively, with the VH, VL, and CL domains 
that are common in the amino acid sequences. We have established a 
cell fine Ex-3C7, which produces mouse monoclonal nti-Ex-A IgG1 (r) 
[18]. This monoclonal ntibody has been demonstrated to recognize the 
amino acid residues 241 to 297 in domain Ia and II of Ex-A, to inhibit 
incorporation of Ex-A into target cells, to neutralize strongly cytotox- 
icity in cell culture [18-20]. It has also been shown that the Ex-3C7 
antibody does not inhibit the enzymatic activity of ADP-ribosyltrans- 
ferase but are protective against pseudomonal infection caused by Ex- 
A-producing strains in experimental mouse models [18-20]. The amino 
acid sequences of the VH and VL domains were determined on the basis 
of DNA sequence data according to the procedure described in the 
literature [21]. 
Hereafter, the Fab fragments that are derived from cell lines 27-44, 
27-13.6, 27-35.8, and Ex-3C7 will be referred to as anti-dansyl Fab(T1), 
anti-dansyl Fab(y2a), anti-dansyl Fab(y2b), and anti-Ex-A Fab, re- 
spectively. 
2.3. Preparation of isotopically labeled Fab fragments 
Isotopic.ally labeled Fab fragments were prepared as described previ- 
ously [12]. Hybridoma cells were grown in a serum-free medium (Nissui 
NYSF-404) that contains an appropriate [1-~3C]amino acid (and [a- 
lSN]amino acid). For example, IgG selectively labeled with 13C and 15N 
at the methionine carbonyl carbon and the histidine amide nitrogen, 
respectively, was prepared by cultivating cells in the medium where 
unlabeled L-Met and ~.-His had been replaced respectively by an equal 
amount of L-[1-13C]Met and a twice amount of DL-[a-15N]His in the 
presence of 100 mg/ml of L-Ala and 16 mg/ml of fl-chloro-L-alanine. 
After cells were grown, the supernatant was concentrated with an ul- 
trafiltration system (Millipore Minitan) and applied to a protein A 
affinity column (Bio-Rad). Typically 10-20 mg of purified IgG proteins 
were obtained per liter of the cell culture. The purified antibody (5 
mg/ml) was digested by papain at pH 7.0, 37°C, in 75 raM sodium 
phosphate buffer containing 75 mM NaC1, 2 mM EDTA, and 5 mM 
NAN3. The enzyme/substrate ratios (w/w) were 1 : 25, l : 50, and 1 : 25 
for IgG1, IgG2a, and IgG2b, respectively. In the case of IgG1 and 
IgG2a antibodies, L-cysteine" HCI-H20 was added to the digestion 
buffer at concentrations of 2 mg/ml and 2 gg/ml, respectively. The 
incubation times were 2 h, 6h, and 8h for IgG1, IgG2a, and IgG2b, 
respectively. The reaction was terminated by addition of 30 mM of 
N-ethylmaleimide. The digestion products were loaded onto a Pharma- 
cia Mono Q FPLC column equilibrated with 20 mM Tris-HC1, pH 8.0, 
and Fab fragments were separately eluted from other products by 
increasing the NaC1 concentration up to 400 raM. Purity of the Fab 
preparations was checked by SDS-PAGE. The size of an antigen-Fab 
complex was determined by use of a Pharmacia Superose 6 gel filtration 
column. 
In the present paper, an Fab analog selectively labeled with 
[l-13C]Met is designated using the one-letter abbreviation for the amino 
acid as [M]Fab. An Fab analog that is doubly labeled with [1-13C]Met 
and [a-15N]His will be designated as [M,H]Fab. Similar notations will 
be used for all labeled Fab analogs. 
2.4. NMR measurements 
For NMR measurements, he Fab solutions were concentrated toa 
final volume of 2 ml in 5 mM sodium phosphate buffer, pH 7.4, contain- 
ing 200 mM NaC! and 3 mM NaN3 in 21-120. The final concentration 
of the Fab was 0.2~).7 mM. NMR measurements were made on a 
Bruker AM 400 spectrometer, t3C-NMR spectra were recorded at 100 
MHz by using a WALTZ 16 composite pulse decoupling sequence. The 
free induction decay was recorded with 32 K data points, a spectral 
width of 24,000 Hz, and a repetition period of 1 s. The free induction 
decay was multiplied by a Gaussian window function prior to Fourier 
transformation. Chemical shifts are given in ppm from internal di- 
oxane. The probe temperature was 30 ° C. 
3. Results and discussion 
In the previous paper, we have mapped the binding 
site of DNS-Lys in an anti-dansyl Fv fragment using 
carbonyl 13C resonances from Cys, His, Met, Trp, and 
Tyr as spectroscopic probes [13]. On the basis of the 
chemical shift data obtained, we have concluded that the 
CDR3 loop in the VH domain is significantly perturbed 
upon addition of DNS-Lys and, therefore, is primarily 
responsible for the binding of DNS-Lys [13]. This con- 
clusion was confirmed by stable-isotope-assisted 
NOESY experiments [22]. We are extending the 13C 
NMR strategy on the basis of chemical shift data of the 
carbonyl carbon to the analyses of the interactions be- 
tween DNS-Lys and anti-dansyl Fab(71), Fab(y2a), and 
Fab(y2b) fragments. The anti-dansyl Fab fragments 
used in the present study possess the VH and VL domains 
composed of the amino acid sequences identical with 
those of the anti-dansyl Fv fragments. 
Fig. 1A shows the 13C NMR spectrum of the anti- 
dansyl [W]Fab(y2b) fragment. The site-specific assign- 
ments for each of the Trp resonances have been reported 
in a previous paper [13]. Upon addition of DNS-Lys, 
resonances originating from Trp°101H and Trp-105H, 
which are located in and at the end of the CDR3 in the 
Va domain, respectively, exclusively showed large chem- 
ical shift changes of more than 0.1 ppm (Fig. 1B)*. These 
* The numbering system used in the present paper for the constant 
region is based on human myeloma protein Eu for the heavy chain [32] 
and mouse myeloma protein MOPC21 for the light chain [26]. The 
convention of Kabat et al. [26] has been followed for the numbering of 
the Vn and VL regions. The notations H and L following the residue 
numbers mean the heavy and light chains, respectively, e.g. Trp-101H 
means Trp-101 in the heavy chain. 
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Fig. 1. 100-MHz 13C NMR spectra of (A) anti-dansyl [W]Fab(T2b) in 
the absence of DNS-Lys, (B) anti-dansyl [W]Fab(y2b) in the presence 
of DNS-Lys, and (C) anti-dansyl [W]Fab(y2a) in the presence of DNS- 
Lys. Protein concentrations and the pH of the sample solutions were 
0.4-0.7 mM and 7.4, respectively. The probe temperature was 30°C. 
51,000-70,000 transients were accumulated for each spectrum, where 
32 K data points and a spectral width of 24,000 Hz were used with a 
repetetion period of 1 s. In the spectra (B) and (C), the molar ratio of 
Fab/DNS-Lys was 1 : 1. Assignments of Trp-36H and Trp-47H may be 
reversed because both of these Trp residues are followed by Val [13]. 
spectral changes were also observed in the case of the 
[W]Fv [13], [W]Fab(y2a) (Fig. 1C), and [W]Fab(y1) frag- 
ments (data not shown). On the basis of these observa- 
tions, we suggest that the binding mode of DNS-Lys is 
unaffected by the existence of the constant domains, and 
also by the difference between the subclasses. This result 
was confirmed by use of Met resonances as spectroscopic 
probes (data not shown) and is quite consistent with the 
fluorescence spectral data [23] and also with the fact that 
dissociation constants of DNS-Lys are identical for the 
IgG1, IgG2a, and IgG2b antibodies and the Fv fragment 
[23-25]. As demonstrated above, we have successfully 
established the NMR strategy to identify the residues in 
the Fab fragments that are specifically perturbed upon 
hapten binding. 
Next, we attempted to extend this method toward 
much larger systems. Here we use a complex of Ex-A and 
anti-Ex-A Fab as an example. Fig. 2 shows the amino 
acid sequences ofthe VH and VL domains of the anti-Ex- 
A Fab. For the spectral assignments of an Fab that is 
newly dealt with, we compare the spectrum with that of 
homologous Fab whose resonances have already been 
assigned. Fig. 3A and B compare the 13C NMR spectra 
of the anti-dansyl [M]Fab(y1) and anti-Ex-A [M]Fab 
fragments. Both of these two Fab fragments are of the 
IgGl(x) isotype. In a previous paper, we have completed 
the site specific assignments of the Met resonances orig- 
inating from the anti-dansyl Fab(y1) as shown in Fig. 3A 
[12]. Anti-Ex-A Fab possesses five Met residues, i.e. Met- 
20H and Met-80H (V.), Met-33L (VL), Met-139H (CH1), 
and Met-175L (CL). See Fig. 2 and Kabat et al. [26]. The 
resonances originating from the constant region, i.e. 
Met-139H in the CH1 domain and Met-175L in the CL 
domain, have their counterparts in the spectrum of anti- 
VH 
! 20 
Glu Va] Gin Leu Gin Gln Set 617 Pro Glu Leu Val L~s Pro GII Ala Ser VIa Arg Net 
2L 31 32 33 34 35 
Set C~s Lys Ala See GIx TTr Thr Phe Thr Ash Tie As. lie His Trp Val LIs Gin L1s 
CDll 
41 50 51 52 52k 53 54 55 56 57 58 59 
Ala GI7 Gin Gl~ Lea GI. Leg Ile GIx Tlr Thr Ash Pro TTr Ash Asp VaI Set b~s Tit 
CDB2 
60 6I 62 63 64 85 
Ash Glu LYs Phe L1s Gly bTs Ala Thr Leg Thr Set Asp L1s Set Set Set Thr Yal TXr 
80 82 82k 82B 82C 83 95 96 
Her GIg Leo Set Ser Leg Thr Ser Gig Asp Set Ale Va] T1r T1r C~s Ala Arg Phe LTs 
97 98 99 IO0 lOOkiOOXlO1 102 
Asp Gly Tit Set Set Phe Ala TTr Trp GII Gin G17 ThP Leu Val Thr Vel Set Ale 
CD23 
1 
Asp Ile Val Lel Thr Gln Set Pro Ala Ser Leu Ala Vtl Set Leu Gll Gl. Arc kla Thr 
23 24 25 26 27 27A 27B 27C 27D 28 29 30 31 32 33 34 35 
Ile Set C~s ~r.K kla See L~s Set Vii Set Thr Set Gll Tlr Set TTr Met His Trp TTr 
CDRI 
37 49 50 51 52 53 54 55 58 
G]n Gin Lys Pro Gly Gin Pro Pro Arg Leu Lea lie Txr Leu Ala $er ASh Leu Glu Ser 
CDR2 
57 62 71 
GIx Val Pro AIa Arg Phe Set GII Set G17 See GIX Thr Asp Phe Thr Lea Ash lie His 
77 88 89 90 91 92 93 94 95 96 
Pro Yal GIu Glu Glu Asp AIa kla Ash Tit His CXs Gin His Set Arg Asp Le~ Pro Leu 
CDR3 
97 98 108 
Thr Phe GI7 All GI7 Thr L1s Leg GIu Leg Lls krg 
Fig. 2. The amino acid sequences of the VH and V L domains of the 
anti-Ex-A Fab used in the present study. 
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Fig. 3. 100-MHz 13C NMR spectra of (A) anti-dansyl [M]Fab(71), (B) 
anti-Ex-A [M]Fab, and (C) anti-Ex-A [M,H]Fab. Protein concentra- 
tions were 0.2--0.4 mM. 51,000-198,000 transients were accumulated. 
Other spectral conditions were as in Fig. 1. In the spectrum (C), the 
Met-33L resonance, which is split into a doublet due to spin coupling 
with ]SN, is indicated by the arrow. 
Ex-A [M]Fab, i.e. resonances a and e, respectively, as 
shown Fig. 3B. Thus, we were able to identify the three 
resonances originating from the variable region of the 
anti-Ex-A [M]Fab, i.e. b, c, and d. 
Site-specific assignments of the resonances originating 
from the variable region of the anti-Ex-A [M]Fab were 
made by the 13C-]5N double labeling method [10-12]. 
Fig. 3C shows a 13C NMR spectrum of the anti-Ex-A 
[M,H]Fab fragment, where resonance d is split into dou- 
blet due to IJcN spin coupling. Among the five Met resi- 
dues existing in the anti-Ex-A [M]Fab, only Met-33L in 
the VL domain is directly followed by His as shown in 
Fig. 2. Therefore, resonance d was unambiguously as- 
signed to Met-33L in the V L domain. 
Upon addition of Ex-A, the Met-33L resonance was 
shifted downfield by 0.2 ppm (Fig. 4). Gel-filtration 
HPLC analysis demonstrated that the anti-Ex-A Fab 
and Ex-A form a 1:1 complex with a molecular mass of 
120 kDa under the solution condition employed for the 
present NMR measurement. On the basis of these obser- 
vations, we conclude that a microenvironment surround- 
ing Met-33L located in the CDR2 in the VL domain is 
significantly perturbed upon binding to Ex-A, while 
those of the other Met residues are little affected. Line 
broadening was observed for Met-33L beyond what had 
been expected from the increase of the molecular size. An 
interesting possibilty is that a microenvironment sur- 
rounding Met-33L in the complex fluctuates between 
multiple states. Specific spectral changes induced by Ex- 
A binding were also observed in the ~3C NMR spectra 
obtained by use of the anti-Ex-A [W]Fab and anti-Ex-A 
[F]Fab (data not shown). 
Quantitative interpretation of the structural changes 
on the basis of the chemical shift and line width data is 
quite difficult at the present stage. However, it should be 
emphasized that, in many systems, larger chemical shift 
changes are observed in the region that has been indi- 
cated by X-ray crystallography to be responsible for 
ligand binding [27-31]. The 13C NMR approach em- 
ployed in the present study will open up a new way for 
the molecular structural analyses of larger systems in- 
! 
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Fig. 4. 100-MHz 13C NMR spectra of anti-Ex-A [M]Fab (A) in the 
absence and (B) in the presence of Ex-A. 198,000-275,000 transients 
were accumulated. In the sp~trum (B), the molar ratio of Fab/Ex-A 
was 1 : 1. Other spectral conditions were as in Fig. 1. 
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cluding Fab fragmnets such as idiotype-anti-idiotype an- 
tibody interactions and Fc-rheumatoid factor interac- 
tions. 
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